NCT00035945View on ClinicalTrials.gov

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 1, 2001

Primary Completion Date

May 1, 2004

Study Completion Date

May 1, 2004

Conditions
Hepatitis C, Chronic
Interventions
DRUG

ISIS 14803

Trial Locations (1)

92008

Isis Pharmaceuticals, Carlsbad

Sponsors
All Listed Sponsors
collaborator

Hepasense

INDUSTRY

collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Ionis Pharmaceuticals, Inc.

INDUSTRY